Stipple Bio Inc. launched with $100 million in Series A financing on April 6, 2026.
Funding supports progression of lead drug STP-100, an antibody-drug conjugate.
Company focuses on novel oncology targets, tumour-specific epitopes, and more precise targets on cancer proteins.